SHPH

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) - 10-Q Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly report (Form 10-Q) for the period ended September 30, 2025. Shuttle Pharmaceuticals is a discovery and development-stage biopharmaceutical company focused on developing novel cancer therapies, specifically radiation sensitizers (Ropidoxuridine) and HDAC inhibitors. The company operates as a single segment and is currently in a pre-revenue stage, relying on equity and debt financing to fund operations and clinical trials.

Key Financial Metrics

Note: The company reported no revenue for the periods presented. Net loss per share (basic and diluted) was $(1.05) for the quarter and $(7.22) for the nine-month period.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses for the nine months ended Sept 30, 2025, increased by 54% to $9.13 million compared to $5.92 million in the prior year period. This was driven by a 297% increase in General and Administrative (G&A) expenses (to $3.83 million), largely due to $2.5 million in investor relations and filing costs. Research and Development (R&D) expenses increased 35% to $3.54 million due to clinical trial initiation costs.
• Other Income/Expense: Other expenses improved significantly, turning from a $1.63 million loss in the prior year to a $21,815 gain in the current period. This was primarily due to the absence of a $0.83 million loss on convertible debt settlement recorded in 2024 and a reduction in interest expense.
• Liquidity: Cash and cash equivalents increased to $2.09 million from $1.92 million at year-end 2024, supported by equity raises in March ($5.0 million net) and June ($3.9 million net) 2025.

Outlook, Risks, and Unusual Items

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. Existing cash and financing are insufficient to fund operations and clinical trials through the next 12 months without additional capital.
• Recent Financing: In November 2025 (subsequent to the period end), the company closed a private placement raising approximately $2.5 million in gross proceeds via pre-funded warrants.
• CRO Termination: On October 15, 2025, the company's primary Contract Research Organization (CRO), Theradex Systems, Inc., terminated its master agreement and demanded immediate payment of $1.1 million in outstanding amounts. This introduces significant uncertainty regarding the continuity of the Ropidoxuridine Phase II clinical trials.
• Strategic Acquisition: On October 20, 2025, the company entered a binding term sheet to acquire substantially all assets of "Molecule" for $10 million (cash and stock), subject to milestones and definitive agreements.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of September 30, 2025, citing material weaknesses in financial reporting oversight, IT general controls, and communication of material contracts.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.5 million raised in November 2025 against the $1.1 million immediate debt to Theradex and ongoing burn rate.
• Clinical Continuity: Confirm the status of the Ropidoxuridine Phase II trial following the termination of the Theradex agreement and the identification of a replacement CRO.
• Debt Obligations: Review the terms of the $2.0 million revolving credit facility (undrawn as of Sept 30) and the fair value accounting of remaining convertible notes.
• Internal Controls: Assess the progress of remediation efforts regarding the identified material weaknesses in financial reporting and IT controls.
• Acquisition Terms: Monitor the execution of definitive agreements for the Molecule acquisition and the impact of the $10 million purchase price on future dilution.